MiR-103b has been shown to target several molecules which play a role in carcinogenesis in other cell types, for example CCNE1, CDK2, CREB1, DICER, and PTEN [62] [44], and colorectal cancer cell line studies indicate dysregulation of miR-103b expression can drive cancer progression [62–64]. This evidence concerns the gene CDK2 and cancer.